“Federal agencies have shown themselves reluctant to act against unreasonable prices, and this new proposal may give them permission to continue to do nothing,” said one expert.
By Brett Wilkins. Published 12-7-2023 by Common Dreams
While welcoming the White House’s willingness to tackle pharmaceutical companies’ patent abuse and high prescription drug prices, progressive critics argued Thursday that U.S. President Joe Biden must do more to challenge Big Pharma’s monopoly power.
The White House on Thursday announced “new actions to promote competition in healthcare and support lowering prescription drug costs for American families, including the release of a proposed framework for agencies on the exercise of march-in rights on taxpayer-funded drugs and other inventions.”
Continue reading
